News Sentiment

CGTX sentiment intelligence

Cognition Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 52 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 1.09 Week of 10 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

82/100 classification confidence.

Company focus 44

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-6.8% over one week, -9.9% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Positive

Cognition Therapeutics Participating in Fireside Chat at B. Riley Securities' Mind, Muscle & Vision Summit

Market Reaction

Price moving ahead of tone

67/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 82/100 classification
One-week reaction -6.8% Price reacting lower
Trend fit Trend inactive -9.9% over four weeks
Fair value -11.2% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 15
Neutral 33
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 44
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Market source 9
Stock Titan 9
TradingView 8
GlobeNewswire 6
Investing.com 3
simplywall.st 3
Moomoo 2
MT Newswires 2

Event Lens

What the news is about

Classified themes
Market update 31
Earnings 14
Analyst action 4
Balance sheet 2
Regulatory and legal 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-52 of 52
Market source Direct company coverage

Cognition Therapeutics Announces New Composition of Matter Patent, Extending Patent Protection for Lead Candidate, Zervimesine (CT1812) Through 2045

Cognition Therapeutics has received a Notice of Allowance for a new composition of matter patent for a polymorphic crystalline form of its lead drug candidate, zervimesine (CT1812). This patent will extend protection for the drug through 2045, potentially to 2050 with extensions.

Tone
Positive 95/100
Event
Market update
Published
20 Jun 2026 23:11
Source
Market source
The Globe and Mail Direct company coverage

Cognition Therapeutics Shareholders Elect Directors, Ratify Auditor

Cognition Therapeutics shareholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors to serve until the 2029 Annual Meeting and ratified Ernst & Young LLP as the independent registered public accounting firm for the 2026 fiscal year. An analyst rating indic

Tone
Positive 58/100
Event
Analyst action
Published
20 Jun 2026 05:11
Source
The Globe and Mail
Investing.com Nigeria Direct company coverage

Cognition Therapeutics elects directors and ratifies auditor at annual meeting By Investing.com

Cognition Therapeutics Inc. (NASDAQ: CGTX) announced the results of its annual meeting, where shareholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors. Additionally, shareholders ratified the appointment of Ernst & Young LLP as the independent register

Tone
Positive 65/100
Event
Earnings
Published
18 Jun 2026 17:10
Source
Investing.com Nigeria
Investing.com Direct company coverage

Cognition Therapeutics elects directors and ratifies auditor at annual meeting

Cognition Therapeutics, Inc. held its annual meeting where shareholders elected Aaron Fletcher, Ph.D., and Lisa Ricciardi as Class II directors. Stockholders also ratified Ernst & Young LLP as the independent auditor for the 2026 fiscal year. These decisions were announced follow

Tone
Positive 67/100
Event
Market update
Published
18 Jun 2026 16:40
Source
Investing.com